Nautilus Biotechnology Inc Stock Price, News & Analysis

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its Q2 2022 financial results, showing total operating expenses of $15.5 million, a decrease from Q1 2022. The company anticipates launching its proteome analysis platform by mid-2024, with early access revenue expected in early 2024. Although operating expenses increased 45% year-over-year, driven by a rise in headcount, cash reserves totaled $334.9 million as of June 30, 2022, extending the cash runway into 2025. The CEO expressed confidence in the company’s strategic direction amidst macroeconomic challenges.

Nautilus Biotechnology expands its leadership team with two significant managerial appointments, enhancing its focus on **proteomics**. Eric Spence joins as Vice President of Instrument Engineering, bringing experience from Genapsys and Agilent, where he advanced DNA sequencing technologies. Ken Kuhn, Ph.D., is appointed Vice President of Reagent and Platform Development, previously with Encodia and Illumina, where he contributed to leading life sciences products. These additions aim to strengthen Nautilus's mission of democratizing access to the proteome, a critical step toward advancing human health.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will release its second quarter 2022 financial results on August 2, 2022, before market open. A conference call will follow at 5:30 a.m. PT to discuss results, business developments, and future outlook. Nautilus is focused on developing a single-molecule protein analysis platform aimed at advancing proteomics for improved health and medicine.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported first-quarter financial results for 2022, revealing a net loss of $15.8 million, up from $8.4 million last year. Operating expenses surged by 90% to $16.0 million, primarily due to increased headcount and public company costs. Despite these financial setbacks, Nautilus highlighted significant scientific achievements, including advancements in single-molecule protein arrays and collaborations with Genentech. Cash reserves stood at $349.0 million as of March 31, 2022.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D. as Vice President of Affinity Reagent Development, enhancing its senior leadership team. Weld brings over 25 years of experience from companies like Microsoft and Amperity, focusing on building a high-performance culture. Dr. Wilcox joins from SomaLogic, where she developed critical proteomic technologies. These appointments are part of Nautilus's strategic expansion to advance its protein analysis platform, aimed at transforming healthcare diagnostics.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q1 2022 on May 3, 2022, before market opening. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results and business outlook. The event will be available for live audio streaming on the company’s investors' page. Nautilus is focused on advancing proteomics technology to enhance healthcare. For more information, visit www.nautilus.bio.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced key presentations at upcoming scientific conferences. Co-founder Parag Mallick, Ph.D., will present at the XIV Annual Congress of the European Proteomics Association in Leipzig, Germany, on April 6, 2022, discussing their novel single-molecule proteomics analysis platform. Associate Director Greg Kapp, Ph.D., will present a poster at the AACR Annual Meeting in New Orleans, LA, on April 13, 2022, focusing on protein identification techniques. These engagements highlight Nautilus' commitment to advancing proteomics and its potential impact on human health.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has appointed Karen Akinsanya, Ph.D., as a new member of its Board of Directors. Dr. Akinsanya brings over 25 years of experience in drug discovery, development, and commercialization. Currently serving as President of R&D at Schrödinger, she has a strong background in clinical pharmacology and business development from her tenure at Merck Research Laboratories. Her leadership is expected to enhance Nautilus’ strategy for the commercialization of its innovative protein analysis platform aimed at improving human health.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its fourth quarter and fiscal year 2021 results, highlighting key achievements and financial metrics. The company completed a business combination with ARYA Sciences Acquisition Corp III, generating approximately $345.5 million. Operating expenses soared 221% to $50.5 million, while net loss widened to $50.3 million from $15.6 million year-over-year. Nautilus announced collaborations with Amgen and MD Anderson, and a strategic partnership with Abcam. As of December 31, 2021, cash and investments totaled $362.1 million, supporting ongoing development.